| TRI
Sections |
 |
SENIOR
TRI INVESTIGATORS AND ADMINISTRATORS
Treatment
Research Solutions Group
 Ms.
Meghan Love, Senior Program Manager, has significant past project
experience that includes management of counselor training studies on electronic
resource guides linking substance abuse patients to low-cost auxiliary
services (NIDA and NIAAA funding), and coordination of a NIDA R21 Exploratory
Grant evaluating a concurrent recovery monitoring project in the state
of Delaware. From 1998 to 2004 she managed the ONDCP-funded DENS project,
a multi-site electronic data collection and reporting system that tracked
patterns of drug and alcohol abuse across the nation. Other NIDA-funded
studies she managed include, in collaboration with the University of Pennsylvania,
a study of patient-treatment matching utilizing the ASI as the primary
data collection tool; development of an Employee Assistance Program survey
estimating the prevalence of drug and alcohol abuse in school and workplace
populations; and development of the Substance Abuse Relapse Reduction
System (SARRS) for early detection of individuals at high risk for relapse
during the critical first six months of the post-treatment recovery period.
The empirically-developed products and services Ms. Love has helped TRI
introduce include the Risk and Needs Triage™ helping court officials
assign drug-involved offenders to the appropriate disposition; TRI-CEP™,
a web-based system to adaptively manage clients and conduct problem-solving
court evaluation; and CASPAR-C™, an electronic patient assessment
and referral system.
 Van
Lam, Web Product Developer, provides technical
leadership to teams of researchers, administrators and other specialists
on science-based product development. He also serves as technical liaison
to state and local government purchasers for adaptive, support and training
functions. Mr. Lam led technical development of TRI’s Risk and Needs
Triage™, TRI-CEP™, and CASPAR-C™, a software application
helping treatment counselors create a searchable database of patient services
available in their area. He was senior developer for the ONDCP-funded
DENS™, an ASI-based patient assessment tool linking client assessment
to treatment planning. Other pending projects include an electronic decision
support system enabling continuous recovery monitoring at the provider
level. Mr. Lam joined TRI in 1996 following other positions in the Philadelphia
area at Merck Pharmaceuticals and Corning-Besselaar. He is a 2002 graduate
of Drexel University where he earned a Bachelor of Science in Computer
Science.
Clinical
Trials Network
 George Woody, M.D., Principal Investigator: Dr. Woody
is a Professor in the Department of Psychiatry at the University of Pennsylvania.
Following a long career in the mental health and substance abuse fields,
his research began in 1971 at the Drug Dependence Treatment Unit of the
Philadelphia Veterans Affairs Medical Center (VAMC) and the University
of Pennsylvania where his overall interest became the efficacy of psychosocial
and pharmacological treatments for addiction; the relationship between
drugs of abuse, psychiatric symptoms, and treatment outcome; and on risk
factors for HIV infection among persons who abuse drugs and how risk can
be reduced. He has been an active participant in projects evaluating naltrexone
(in the U.S. and in Russia), psychotherapy and counseling for persons
with cocaine dependence, and buprenorphine for treatment of heroin addiction.
In 1999 he became the principal investigator of the Delaware Valley Node
of the National Institute on Drug Abuse Clinical Trials Network (CTN,
and in 2003, received a Senior Scientist award from the National Institute
of Drug Abuse to allow him to spend less time on clinical work and more
on research. Dr. Woody’s numerous accomplishments and affiliations
include authoring or co-authoring more than 200 publications and co-editing
Treatment Improvement Protocols on methadone maintenance published by
the U.S. Substance Abuse and Mental Health Administration. He helped develop
Addiction Treatment Practice Guidelines for the Department of Veterans
Affairs, is a member of research groups studying the abuse liability of
tramadol and prescription opioids, and is a founding member of the Board
of Addiction Psychiatry of the American Psychiatric Association.
|